Analyst consensus rating
Telix Pharmaceuticals Analyst Rating: none
Direct answer
Telix Pharmaceuticals's consensus rating is none.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $19.86.
Forecast evidence checked November 13, 2026.
Get free Telix Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $9.36
- Average price target
- $19.86
- High price target
- $21.30
- Low price target
- $17.39
- Low target gap
- +85.8%
- Target upside
- +112.2%
- High target gap
- +127.6%
- Target range width
- 41.8%
- Consensus rating
- none
- Analysts
- 4
- Evidence date
- November 13, 2026
- Valid through
- November 20, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Telix Pharmaceuticals?
Telix Pharmaceuticals has a verified none consensus. The same dataset has an average price target of $19.86.
How far are Telix Pharmaceuticals's low and high targets from the recorded price?
The low target implies +85.8%, while the high target implies +127.6%.
How many analysts are included in Telix Pharmaceuticals's consensus?
The verified consensus includes 4 analysts.
How is Telix Pharmaceuticals's target upside or downside calculated?
The average target of $19.86 is divided by the recorded price of $9.36, then one is subtracted to produce +112.2%. This does not guarantee a future return.
When was Telix Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-13. The dataset is valid through 2026-11-20.